PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies.

According to this latest report, "PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services", the driver of this early development activity has been the huge level of external funding flowing into emerging bio/pharma companies from venture capitalists and public markets. However, external funding for bio/pharma has always been a "boom or bust" proposition, and the likelihood that funding will be cut drastically always lurks on the horizon. This makes it difficult for CDMOs and CROs to pull the trigger on investments in new capacity.

Request sample copy at: https://www.reportsweb.com/inquiry&RW0001608622/sample

Report Scope

- Follow the Money: The Outlook for Outsourced Spending on Early Development Services exams the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years.

Key Attributes of Report:

This report provides important insight that you won't find in any other source. This report is required reading for -
- CDMOs and CROs: market trends, capital investment decision-making, strategic planning, performance benchmarking
- Bio/pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity: investment targeting, portfolio company performance benchmarking

Have any query? Enquire about report at: https://www.reportsweb.com/inquiry&RW0001608622/buying

1 Table of Contents
Executive Summary 1
Context and Objectives 2
Clinical Trial Activity of Emerging Bio/Pharma Companies 4
Clinical Development Costs and Spending by Emerging Bio/Pharma Companies 7
External Financing for Emerging Bio/Pharma Companies 9
Outlook and What it Means 15
Appendix A 18
Appendix B 19

List of Tables

Table 1 2016 Performance of Drug Development Service Providers
Table 2 Profile of Emerging Bio/Pharma IPOs 2014-2015

List of Figures

Figure 1 Breakdown of Phase I and Phase II Trials by Primary Sponsor, H1 2012-H1 2016
Figure 2 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-IPO
Figure 3 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-SPO
Figure 4 Estimated Cost of Getting Candidates Through Clinical Trial Phases
Figure 5 Ownership of Emerging Bio/Pharma Companies Sponsoring Clinical Trials H1 2016
Figure 6 Equity Funding to Emerging Bio/Pharma 2010-2016
Figure 7 Venture Capital Investment in Bio/Pharma Companies
Figure 8 VC Funding to Emerging Bio/Pharma 2010-2015
Figure 9 NASDAQ Biotech Index January 13-December 2016
Figure 10 R&D Spend and Cash Runway for US Emerging Bio/Pharma Companies
Figure 11 Revenue as a Funding Source for US Emerging BioPharma
Figure 12 Proportion of Companies with > 2 Years Cash or Increasing Cash Reserves

Get more information at: https://www.reportsweb.com/inquiry&RW0001608622/discount

About ReportsWeb:

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

This release was published on openPR.